Granisetron Hydrochloride

The 5-HT3 receptor, also known as the serotonin receptor, plays a crucial role in the human body. It is primarily found in the central and peripheral nervous systems, particularly in the gastrointestinal tract and the brain. Activation of the 5-HT3 receptor by serotonin, a neurotransmitter, leads to various physiological responses such as regulating mood, appetite, and sleep. Additionally, this receptor is involved in the regulation of nausea and vomiting, making it a target for antiemetic drugs used in chemotherapy and postoperative settings. Understanding the role of the 5-HT3 receptor is essential for developing therapeutic interventions that can modulate its activity and potentially treat various disorders related to serotonin dysregulation. 5-HT3 receptor antagonists, also known as serotonin receptor antagonists or serotonin blockers, are a class of medicines used for the prevention and treatment of nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or postoperatively. The first 5-HT3 receptor antagonist, ondansetron, was developed by Glaxo around 1984 and its efficacy was first established in 1987. It was approved by the U.S. Food and Drug Administration in 1991. The analysis of the target 5-HT3 receptor reveals a competitive landscape with multiple companies actively involved in the development of drugs. The highest stage of development is the approved phase, indicating successful clinical trials and regulatory approval. Drugs targeting the 5-HT3 receptor have been approved for various indications, with nausea being the most common indication. Small molecule drugs are progressing rapidly, indicating intense competition. China, the United States, and Japan are the leading countries in the development of drugs targeting the 5-HT3 receptor, with China showing significant progress. Overall, the target 5-HT3 receptor presents opportunities for further research and development in the pharmaceutical industry. How do they work?5-HT3 receptor antagonists are a class of drugs that block the action of serotonin on the 5-HT3 receptors in the central nervous system and peripheral tissues. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter that plays a role in various physiological functions, including mood regulation, gastrointestinal motility, and vomiting reflex. From a biomedical perspective, 5-HT3 receptor antagonists are commonly used in the management of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. By blocking the activation of 5-HT3 receptors, these drugs help to reduce the signals that trigger the vomiting reflex, thus alleviating nausea and vomiting symptoms. Some examples of 5-HT3 receptor antagonists include ondansetron, granisetron, and palonosetron. These drugs are typically administered orally or intravenously, and their use is well-established in clinical practice. They are considered effective and safe for the prevention and treatment of chemotherapy-induced and postoperative nausea and vomiting. However, like any medication, they may have potential side effects, such as headache, constipation, and dizziness. In summary, 5-HT3 receptor antagonists are drugs that block the action of serotonin on specific receptors in the central nervous system and peripheral tissues. They are commonly used to manage nausea and vomiting associated with various medical treatments and surgeries. List of 5-HT3 receptor AntagonistsThe currently marketed 5-HT3 receptor antagonists include: Netupitant/Palonosetron HydrochlorideVortioxetine HydrobromideTropisetron CitrateGranisetronIndisetron HydrochloridePalonosetron hydrochlorideTropisetron MesylateAlosetron HydrochlorideDolasetron MesylateFor more information, please click on the image below. What are 5-HT3 receptor antagonists used for?5-HT3 receptor antagonists are commonly used in the management of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. For more information, please click on the image below to log in and search. How to obtain the latest development progress of 5-HT3 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of 5-HT3 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

The urge to vomit after eating contaminated food is the body's natural defensive response to get rid of bacterial toxins. However, the process of how our brain initiates this biological reaction upon detecting the germs remains elusive. For the first time, researchers mapped out the detailed neural pathway of the defensive responses from the gut to the brain in mice. The urge to vomit after eating contaminated food is the body's natural defensive response to get rid of bacterial toxins. However, the process of how our brain initiates this biological reaction upon detecting the germs remains elusive. For the first time, researchers mapped out the detailed neural pathway of the defensive responses from the gut to the brain in mice. The study, presented November 1 in the journal Cell, could help scientists develop better anti-nausea medications for cancer patients who undergo chemotherapy. Many foodborne bacteria produce toxins in the host after being ingested. The brain, after sensing their presence, will initiate a series of biological responses, including vomit and nausea, to get rid of the substances and develop an aversion toward foods that taste or look the same. "But details on how the signals are transmitted from the gut to the brain were unclear, because scientists couldn't study the process on mice," says Peng Cao, the paper's corresponding author at the National Institute of Biological Sciences in Beijing. Rodents cannot vomit, likely because of their long esophagus and weaker muscle strength compared to their body size. As a result, scientists have been studying vomit in other animals like dogs and cats, but these animals are not comprehensively studied and thus failed to reveal the mechanism of nausea and vomiting. Cao and his team noticed that while mice don't vomit, they retch -- meaning they also experience the urge to vomit without throwing up. The team found that after receiving Staphylococcal enterotoxin A (SEA), which is a common bacterial toxin produced by Staphylococcus aureus that also leads to foodborne illnesses in humans, mice developed episodes of unusual mouth opening. Mice that received SEA opened their mouths at angles wider than those observed in the control group, where mice received saline water. Moreover, during these episodes, the diaphragm and abdominal muscles of the SEA-treated mice contract simultaneously, a pattern seen in dogs when they are vomiting. During normal breathing, animals' diaphragm and abdominal muscles contract alternatively. "The neural mechanism of retching is similar to that of vomiting. In this experiment, we successfully build a paradigm for studying toxin-induced retching in mice, with which we can look into the defensive responses from the brain to toxins at the molecular and cellular levels," Cao says. In mice treated with SEA, the team found the toxin in the intestine activates the release of serotonin, a type of neurotransmitter, by the enterochromaffin cells on the lining of the intestinal lumen. The released serotonin binds to the receptors on the vagal sensory neurons located in the intestine, which transmits the signals along the vagus nerves from the gut to a specific type of neurons in the dorsal vagal complex -- Tac1+DVC neurons -- in the brainstem. When Cao and his team inactivated the Tac1+DVC neurons, SEA-treated mice retched less compared with mice with normal Tac1+DVC neuron activities. In addition, the team investigated whether chemotherapy drugs, which also induce defensive responses like nausea and vomiting in recipients, activate the same neural pathway. They injected mice with doxorubicin, a common chemotherapy drug. The drug made mice retch, but when the team inactivated their Tac1+ DVC neurons or serotonin synthesis of their enterochromaffin cells, the animals' retching behaviors were significantly reduced. Cao says some of the current anti-nausea medications for chemotherapy recipients, such as Granisetron, work by blocking the serotonin receptors. The study helps explain why the drug works. "With this study, we can now better understand the molecular and cellular mechanisms of nausea and vomiting, which will help us develop better medications," Cao says. Next, Cao and his colleagues want to explore how toxins act on enterochromaffin cells. Preliminary research shows that enterochromaffin cells don't sense the presence of toxins directly. The process likely involves complex immune responses of damaged cells in the intestine. "In addition to foodborne germs, humans encounter a lot of pathogens, and our body is equipped with similar mechanisms to expel these toxic substances. For example, coughing is our body's attempt to remove the coronavirus. It's a new and exciting field of research about how the brain senses the existence of pathogens and initiates responses to get rid of them." Cao says, adding that future research may reveal new and better targets for drugs, including anti-nausea medicines. This work was supported by the National Key R&D Program of China and the National Natural Science Foundation of China.